HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival

Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer

Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations

Medicine, Molecular Biology, Oncology +15

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Mark D. Pegram, A. Lipton, Daniel F. Hayes et al. · Journal of Clinical Oncology · 1998 · 1.1K citations

Medicine, Oncology, Pharmacology +17

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Michael F. Press, Leslie Bernstein, P. Thomas et al. · Journal of Clinical Oncology · 1997 · 810 citations

Medicine, Molecular Biology, Oncology +14

erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

Soonmyung Paik, John Bryant, Chanheun Park et al. · JNCI Journal of the National Cancer Institute · 1998 · 656 citations

Medicine, Pharmacology, Breast Oncology +12

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

Ann D. Thor, Donald A. Berry, Daniel R. Budman et al. · JNCI Journal of the National Cancer Institute · 1998 · 618 citations · Full text

Medicine, Oncology, Pharmacology +16